SCHEMBL5449209

SCHEMBL5449209

O=C(COc1ccccc1)Nc1cccc(-c2cc(C(=O)NO)n[nH]2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.58
▸ SMN1; SMN2 Q16637 5/20 0.58
▸ KDM4E B2RXH2 4/20 0.58
▸ NPC1 O15118 4/20 0.58
▸ LMNA P02545 3/20 0.58
▸ HPGD P15428 3/20 0.58
▸ TSHR P16473 2/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ HAVCR2 Q8TDQ0 5/20 0.57
▸ KMT2A Q03164 4/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ ALDH1A1 P00352 3/20 0.55
▸ POLB P06746 3/20 0.55
▸ RAB9A P51151 3/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ GLA P06280 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ MAPK1 P28482 1/20 0.53
▸ TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4422505 0.85 CFD (0.54) MAPTSMN1; SMN2KDM4ELMNAHPGD
SCHEMBL8290060 0.85 SMN1; SMN2 (0.56) MAPTSMN1; SMN2KDM4ENPC1LMNA
SCHEMBL4427288 0.82 BCHE (0.60) MAPTSMN1; SMN2KDM4ENPC1HPGD
SCHEMBL5944252 0.79 HAVCR2 (0.62) MAPTSMN1; SMN2KDM4ENPC1LMNA
SCHEMBL4566820 0.77 BRD4 (0.53) HPGD
SCHEMBL4552859 0.75 CDK1 (0.57) LMNAHPGDKMT2AMEN1ALDH1A1
SCHEMBL3498895 0.71 LMNA (0.78) MAPTSMN1; SMN2NPC1LMNAHPGD
SCHEMBL8353128 0.71 MAPT (0.63) MAPTSMN1; SMN2KDM4ENPC1LMNA
SCHEMBL8289907 0.71 HDAC6 (0.55) NPC1RAB9A
SCHEMBL19501255 0.71 NPC1 (0.72) MAPTSMN1; SMN2KDM4ENPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 — — US disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 — — US disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 — — US disclosed
WO-2005040161-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications HDAC1, HDAC11, HDAC2 MAPT 3965/4885SMN1; SMN2 4348/4885KDM4E 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback